Key facts
- Steel Therapeutics’s last known valuation is $11.7M (Apr 2022).
- It has raised $9.1M across 4 recorded rounds; the latest was Seed Round ($2.0M) in Nov 2024.
- Notable investors include ISA Ventures, New Bohemian Innovation Collaborative.
- Steel Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently Dec 2024 ($2.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Steel Therapeutics
Funding rounds
4 roundsAbout Steel Therapeutics
Operator of a pharmaceutical company intended to focus on increasing access to therapies that have a track record of efficacy from compounding pharmacies. The company builds retail compounding programs and identifies both high-impact drug candidates and innovative delivery systems, enabling healthcare professionals to analyze scientific literature and provide information regarding novel drug target hypotheses.
- Sector
- Healthcare
- HQ
- North Liberty, IA, United States
- Founded
- 2020
- Employees
- 3
- Website
- steeltherapeutics.com/
- Ownership
- Privately Held (backing)
Steel Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Steel Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Steel Therapeutics in its N-PORT filings yet. We sweep new filings monthly.